Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Developing Resistance With FLT3 Inhibitors in AML

April 28th 2021

Jessica K. Altman, MD, and Naval G. Daver, MD, discuss what is known in terms of mechanisms of resistance to FLT3 inhibitors used to treat acute myeloid leukemia.

Options for CAR-T Therapy in the Third-Line Setting

April 27th 2021

A key opinion leader in diffuse large B-cell lymphoma provides a historical perspective on third-line options for CAR T-cell therapy and shares insights on both clinical trial and real-world data.

First-Line Chemoimmunotherapy for MZL and FL

April 27th 2021

Key opinion leaders in hematology-oncology discuss treatment considerations for first-line chemoimmunotherapy in follicular lymphoma and marginal zone lymphoma and when to use maintenance therapy or observation.

Treatment for Steroid-Refractory Chronic GVHD

April 27th 2021

A review of treatment options for patients with chronic GVHD who don’t respond to steroid therapy and preliminary findings from the phase 3 REACH3 trial.

Unmet Needs in Relapsed/Refractory DLBCL

April 27th 2021

An expert in hematology oncology, Amit Patel, BSc, MBBS, PhD, reviews the unmet needs for patients with relapsed/refractory diffuse large B-cell lymphoma.

Treatment for Steroid-Refractory Acute GVHD

April 27th 2021

Defining steroid-refractory acute GVHD, treatment options for patients who don’t respond to steroid therapy, and a review of the REACH2 trial.

Factors to Consider When Initiating Treatment for MZL and FL

April 27th 2021

Experts in lymphoma provide insight into factors to consider when initiating treatment and emphasize the importance of both clinical judgment and treatment guidelines like the GELF criteria when monitoring patients.

Oral Azacitidine Recommended for EU Approval in AML

April 23rd 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion for the approval of oral azacitidine as a maintenance treatment for adult patients with acute myeloid leukemia who had a complete remission or CR with incomplete blood count recovery after induction therapy with or without consolidation treatment, and who are ineligible for or choose to not undergo hematopoietic stem cell transplant

Venetoclax-Based Regimens Get European Nod for Newly Diagnosed, Chemo-Ineligible AML

April 23rd 2021

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended to approve venetoclax for use in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

Dr. Ansell on the Role of PET Scans in Hodgkin Lymphoma

April 23rd 2021

Stephen M. Ansell, MD, PhD, discusses the role of positron emission tomography scans in patients with Hodgkin lymphoma.

FDA Grants Priority Review to SH-111 for Pediatric T-Cell Leukemia

April 23rd 2021

The FDA has granted a priority review designation to SH-111, a sterile injectable therapy, for the treatment of pediatric patients with T-cell leukemia.

Role of Leptin in the MASP-2 Pathway

April 22nd 2021

Jeffrey Laurence, MD, discusses the role of leptin in the MASP-2 pathway as well as coagulation and complement pathways.

Pagel Unpacks the Utility of PI3K Inhibitors in Lymphoid Malignancies

April 22nd 2021

Dr. Pagel discusses the advances that have been made with PI3K inhibitors in lymphoid malignancies, the impact of the FDA approval of umbralisib on the treatment paradigm in follicular lymphoma and marginal zone lymphoma, and ongoing research poised to expand the armamentarium.

TA-TMA Treatment: Alternative Medications

April 22nd 2021

The panel reviews therapeutic options for managing transplant-associated thrombotic microangiopathy and the challenges associated with currently existing agents.

Unmet Needs and Looking Ahead in Essential Thrombocythemia

April 21st 2021

Unmet needs and current areas that are being studied in in essential thrombocythemia.

The Treatment Spectrum in Essential Thrombocythemia

April 21st 2021

Pankit Vachhani, MD, highlights treatment considerations in low- to high-risk essential thrombocythemia and patients resistant or intolerant to hydroxyurea.

Combination Sorafenib Plus HMA in R/R AML

April 21st 2021

Naval G. Daver, MD, leads the discussion on the use sorafenib in combination with hypomethylating agents (HMA) for the treatment of relapsed FLT3-mutated AML.

Importance of Achieving CR in AML

April 21st 2021

Examining the need to achieve a true CR (complete remission), especially with recent targeted therapies in relapsed/refractory acute myeloid leukemia.

Initial Therapy in GVHD

April 20th 2021

Experts in hematology-oncology share insights on approaching initial treatment and the treatment goals for acute and chronic GVHD.

Diagnosis of Indolent Lymphomas: MZL vs FL

April 20th 2021

Experts in hematology-oncology build a discussion on differences in patient presentation and diagnosis of different types of indolent non-Hodgkin lymphomas such as marginal zone lymphoma and follicular lymphoma.